ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is so contagious that it has caused a global pandemic known as COVID-19. Anti-SARS-CoV-2 antibodies are safe and specific, and have satisfactory neutralizing activities against the virus. As the spike glycoprotein (S protein) of SARS-CoV-2 is critical to virus infection, it is the most important target of neutralizing antibodies. Most of their epitopes are located in the receptor binding domain, while others are located in S2 subunit or S1/S2 hydrolysis site. Serum-derived polyclonal antibodies, monoclonal antibodies, Fc fusion proteins and signle-domain antibodies can be screened out using single-cell sequencing, antibody library, and transgenic mice technologies. A number of antibodies have entered clinical trials, some of which have been authorized by US Food and Drug Administration for emergency use. Here the current developments of anti-SARS-CoV-2 neutralizing antibodies are reviewed, which will be of benefit to COVID-19 treatment. © 2021 Chinese Journal of Pharmacology and Toxicology. All rights reserved.